IND Enabling
Phase I
Phase II
Phase III
Anhui Kedgene Biotechnology
Main focus: Next generation T cell based therapies
Company stage: Clinical
Diseases: Solid tumors
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Anhui, China
Anhui Kedgene Biotechnology develops next generation T cell based therapies for solid tumor treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimize efficiacy and safety.
